Richard Pzena's Hancock Classic Value Q1 2026 Investment Activity Analysis
Detailed analysis of Richard Pzena's investment activities for the first quarter of 2026, including significant purchases and sales in key sectors.
As part of the ongoing monitoring of insider investment activities, we've analyzed the latest filing for Richard Pzena, CEO of Hancock Classic Value, covering the period ending March 31, 2026. The fund's total portfolio value stood at approximately $30.7 billion as of this date.
In this quarter, Pzena made several notable adjustments to the fund's portfolio. Significant selling activity was observed in several holdings, while purchases were concentrated in a few select stocks.
Among the most significant sales during the quarter was the reduction in Magna International Inc. (MGA), where the fund sold approximately 13% of its shares. Similarly, Citigroup Inc. (C) saw a substantial 23% reduction in holdings, and sales were also noted in CVS Health Corp. (CVS), Bristol Myers Squibb Co. (BMY), Baxter International Inc. (BAX), and Capital One Financial Corp. (COF).
On the purchase front, the fund significantly increased its position in Humana Inc. (HUM), adding approximately 34% to its stake during the quarter. Other notable purchases included Cognizant Technology Solutions Corp. (CTSH) and Skyworks Solutions Inc. (SWKS), both seeing increases exceeding 25% in their respective holdings.
These strategic adjustments reflect the fund's approach to capitalizing on perceived value and managing risk within its portfolio. For more detailed information on these transactions, investors can refer to the full filing.
For comprehensive insights into Richard Pzena's investment strategies and Hancock Classic Value's performance, visit Richard Pzena's profile on Insiderset.
For detailed analysis of the companies involved, including Magna International (MGA), Cognizant (CTSH), and others, explore our coverage at Insiderset's stock profiles.